MA47212A - Méthodes de traitement de troubles neurologiques - Google Patents

Méthodes de traitement de troubles neurologiques

Info

Publication number
MA47212A
MA47212A MA047212A MA47212A MA47212A MA 47212 A MA47212 A MA 47212A MA 047212 A MA047212 A MA 047212A MA 47212 A MA47212 A MA 47212A MA 47212 A MA47212 A MA 47212A
Authority
MA
Morocco
Prior art keywords
treatment methods
neurological disorders
neurological
disorders
treatment
Prior art date
Application number
MA047212A
Other languages
English (en)
Inventor
Rebecca Aron
Chee-Yeun Chung
Bourdonnec Bertrand Le
Matthew Lucas
Jeff Piotrowski
Kenneth Rhodes
Robert Scannevin
Eric Solis
Daniel Tardiff
Benjamin Vincent
Original Assignee
Yumanity Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yumanity Therapeutics Inc filed Critical Yumanity Therapeutics Inc
Publication of MA47212A publication Critical patent/MA47212A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA047212A 2017-01-06 2018-01-05 Méthodes de traitement de troubles neurologiques MA47212A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762443066P 2017-01-06 2017-01-06

Publications (1)

Publication Number Publication Date
MA47212A true MA47212A (fr) 2019-11-13

Family

ID=62782012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047212A MA47212A (fr) 2017-01-06 2018-01-05 Méthodes de traitement de troubles neurologiques

Country Status (13)

Country Link
US (2) US10973810B2 (fr)
EP (1) EP3566055A4 (fr)
JP (2) JP2020514293A (fr)
KR (1) KR20190108118A (fr)
CN (1) CN110392833A (fr)
AU (1) AU2018205275B2 (fr)
BR (1) BR112019013954A2 (fr)
CA (1) CA3049010A1 (fr)
EA (1) EA201991650A1 (fr)
IL (2) IL304017A (fr)
MA (1) MA47212A (fr)
MX (1) MX2019008124A (fr)
WO (1) WO2018129403A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2020198026A1 (fr) * 2019-03-22 2020-10-01 Yumanity Therapeutics, Inc. Composés et leurs utilisations
EP4100023A4 (fr) * 2020-02-07 2024-03-13 University of South Florida Inhibition de l'oligomérisation de la bêta-arrestine en tauopathie
WO2022104011A1 (fr) * 2020-11-12 2022-05-19 Yumanity Therapeutics, Inc. Méthodes de traitement de troubles neurologiques
WO2022197975A1 (fr) * 2021-03-18 2022-09-22 Alnylam Pharmaceuticals, Inc. Compositions d'agent d'arni de stéaroyl-coa désaturase 5 (scd5) et procédés d'utilisation associés
WO2024181431A1 (fr) * 2023-02-28 2024-09-06 国立大学法人 長崎大学 Composition favorisant la décomposition d'agrégats protéiques et composition pharmaceutique pour la prévention ou le traitement de maladies neurodégénératives associées à la formation d'agrégats protéiques

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063979A2 (fr) 1998-06-08 1999-12-16 Chavali Sambasiva R Inhibition de l'activite de δ-9-desaturase au moyen de saponines
US20040226056A1 (en) * 1998-12-22 2004-11-11 Myriad Genetics, Incorporated Compositions and methods for treating neurological disorders and diseases
US20070087363A1 (en) * 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
DE60142692D1 (de) 2000-02-24 2010-09-09 Xenon Genetics Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20050043256A1 (en) 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
AU2003215203A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Short interfering nucleic acid inhibition of stearoyl-coa desaturase (scd) gene
AU2004261250B2 (en) 2003-07-29 2009-02-26 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
US7754711B2 (en) 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
RU2006105717A (ru) 2003-07-30 2007-09-20 Зинон Фармасьютиклз Инк. (Ca) Производные пиперазина и их применение в качестве терапевтических агентов
EP1651606B1 (fr) 2003-07-30 2012-10-24 Xenon Pharmaceuticals Inc. Derives pyridyle et leur utilisation en tant qu'agents therapeutiques
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP3042895A1 (fr) 2003-07-30 2016-07-13 Xenon Pharmaceuticals Inc. Dérivés de la pipérazine et leur utilisation en tant qu'agents thérapeutiques
AU2004293092A1 (en) 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin D analogs for obesity prevention and treatment
JP2005213233A (ja) 2004-02-02 2005-08-11 Fuji Oil Co Ltd 肝臓ステアロイル‐ＣｏＡ不飽和化酵素１合成抑制剤
ATE537830T1 (de) 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
WO2006015621A1 (fr) 2004-08-09 2006-02-16 Cellzome Ag Utilisation d'inhibiteurs de scd4 pour le traitement de maladies degeneratives
DE602005025924D1 (en) 2004-09-20 2011-02-24 Xenon Pharmaceuticals Inc Royl-coa-desaturase
TW200626154A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
JP5080256B2 (ja) 2004-09-20 2012-11-21 ゼノン・ファーマシューティカルズ・インコーポレイテッド 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用
JP5149009B2 (ja) 2004-09-20 2013-02-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体
JP5043668B2 (ja) 2004-09-20 2012-10-10 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0515483A (pt) 2004-09-20 2008-07-22 Xenon Pharmaceuticals Inc derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase
US8399438B2 (en) 2004-11-22 2013-03-19 Wisconsin Alumni Research Foundation 2α-methyl-19-nor-1α-hydroxy-homopregnacalciferol and its uses
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
WO2007046868A2 (fr) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de thiazolidine et leurs utilisations en tant qu’agents therapeutiques
WO2007044085A2 (fr) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Composes heteroaryle et leurs utilisations en tant qu'agents therapeutiques
WO2006125181A2 (fr) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Derives piperidiniques: utilisation comme agents therapeutiques
WO2006125179A1 (fr) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Composes tricycliques: utilisation comme agents therapeutiques
WO2006125194A2 (fr) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Derives de piperazine et leurs utilisations en tant qu'agents therapeutiques
MX2007015216A (es) 2005-06-03 2008-02-22 Xenon Pharmaceuticals Inc Derivados de aminotiazol y sus usos como agentes terapeuticos.
WO2006130986A1 (fr) 2005-06-09 2006-12-14 Merck Frosst Canada Ltd. Derives d'azacyclohexane comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
CA2615045A1 (fr) 2005-07-20 2007-01-25 Merck Frosst Canada Ltd. Composes heteroaromatiques servant d'inhibiteurs d'une coenzyme stearoyle a delta-9 desaturase
JP2009515839A (ja) 2005-11-15 2009-04-16 メルク フロスト カナダ リミテツド ステアロイル−ＣｏＡデルタ−９デサチュラーゼ阻害剤としてのアザシクロヘキサン誘導体
WO2007136746A2 (fr) 2006-05-19 2007-11-29 Xenon Pharmaceuticals Inc. Composés macrocycliques et leurs utilisations en tant qu'agents thérapeutiques
CA2651700A1 (fr) 2006-05-22 2007-11-29 Merck Frosst Canada Ltd. Derives d'amines cycliques en tant qu'inhibiteurs de la stearoyl-coenzyme a delta-9-desaturase
ATE486862T1 (de) 2006-06-05 2010-11-15 Novartis Ag Organische verbindungen
CA2654792A1 (fr) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Derives d'azetidine comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
WO2007143824A1 (fr) 2006-06-13 2007-12-21 Merck Frosst Canada Ltd. Dérivés de l'azacyclopentane utilisés en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2008003753A1 (fr) 2006-07-07 2008-01-10 Biovitrum Ab (Publ) Analogues de pyrazolo [1,5-a] pyrimidine utilisables comme inhibiteurs de l'activité stéaroyl-coa désaturase (scd)
EP2057159A1 (fr) 2006-08-09 2009-05-13 Merck Frosst Canada Ltd. Dérivés d'azacycloalcane en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
KR20130036080A (ko) 2006-08-15 2013-04-09 제논 파마슈티칼스 인크. 증가된 지질 수준과 관련된 질환의 치료에 적합한 헤테로시클릭 화합물
BRPI0719122A2 (pt) 2006-08-24 2013-12-10 Novartis Ag Compostos orgânicos
WO2008029266A1 (fr) 2006-09-08 2008-03-13 Glenmark Pharmaceuticals S.A. Inhibiteurs de la stéaroyl coa désaturase
CA2662574A1 (fr) 2006-09-22 2008-03-27 Novartis Ag Composes organiques
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
CA2665476A1 (fr) 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Composes heterocycliques azotes bicycliques pour une utilisation en tant qu'inhibiteurs de stearoyl-coa-desaturase
US20090325956A1 (en) 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
EP2076509A4 (fr) 2006-10-20 2011-02-16 Merck Frosst Canada Ltd Dérivés d'azacycloalcane en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
WO2008056687A1 (fr) 2006-11-09 2008-05-15 Daiichi Sankyo Company, Limited Nouveau dérivé de spiropipéridine
EP2099755A2 (fr) 2006-11-20 2009-09-16 Glenmark Pharmaceuticals S.A. Dérivés d'acétylène comme inhibiteurs de la stéaroyl coa désaturase
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EA200900820A1 (ru) 2006-12-20 2010-02-26 Новартис Аг 2-замещенные 5-членные гетероциклы в качестве ингибиторов стеароил-соа-десатуразы (ссд)
GB0625654D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625594D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625605D0 (en) 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
GB0625604D0 (en) * 2006-12-21 2007-01-31 Smithkline Beecham Corp Compounds
AR064965A1 (es) 2007-01-26 2009-05-06 Merck Frosst Canada Inc Derivados de azacicloalcanos como inhibidores de estearoil - coenzima a delta -9 desaturasa
WO2008096746A1 (fr) 2007-02-06 2008-08-14 Takeda Pharmaceutical Company Limited Composé spiro et son utilisation
EP2125799A1 (fr) 2007-02-28 2009-12-02 Smithkline Beecham Corporation Dérivés de thiadiazole, inhibiteurs de stéoryl-coa désaturase
US20080255153A1 (en) * 2007-03-28 2008-10-16 Biovitrum Ab (Publ) New compounds
WO2008120744A1 (fr) 2007-03-30 2008-10-09 Japan Tobacco Inc. Composé d'amide cyclique à cinq chaînons et son utilisation
WO2008120759A1 (fr) 2007-03-30 2008-10-09 Japan Tobacco Inc. Composé d'urée et son utilisation
WO2008123469A1 (fr) 2007-03-30 2008-10-16 Japan Tobacco Inc. Composé amide à six chaînons et son utilisation
JP2010523653A (ja) 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
US20080255161A1 (en) 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
AU2008241313A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2008139845A1 (fr) 2007-04-24 2008-11-20 Daiichi Sankyo Company, Limited Nouveau dérivé amide
EP2152719A4 (fr) 2007-05-23 2011-01-19 Merck Frosst Canada Ltd Composés hétéroaromatiques bicycliques utilisés en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
JP2009019013A (ja) * 2007-07-12 2009-01-29 Daiichi Sankyo Co Ltd 新規ヘテロアリールピペリジン誘導体
GB0714129D0 (en) 2007-07-19 2007-08-29 Smithkline Beecham Corp compounds
CA2693290A1 (fr) 2007-07-20 2009-01-29 Merck Frosst Canada Ltd. Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
GB0715055D0 (en) 2007-08-02 2007-09-12 Smithkline Beecham Corp Compounds
DE602008003586D1 (de) 2007-08-08 2010-12-30 Graceway Pharmaceuticals Llc Phenoxypyrrolidinderivat, seine verwendung sowie zusammensetzungen daraus
WO2009037542A2 (fr) 2007-09-20 2009-03-26 Glenmark Pharmaceuticals, S.A. Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
GB0721419D0 (en) 2007-10-31 2007-12-12 Smithkline Beecham Corp Compounds
GB0722075D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
WO2009070533A1 (fr) 2007-11-29 2009-06-04 Complegen, Inc. Procédés d'inhibition de stéaroyle-coa désaturase
KR101198582B1 (ko) 2007-12-11 2012-11-06 에프. 호프만-라 로슈 아게 스테아로일-ｃｏａ 불포화화 효소의 억제제
AU2008336224A1 (en) 2007-12-11 2009-06-18 Merck Frosst Canada Ltd Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme A delta-9 desaturase
JP2011507966A (ja) 2007-12-28 2011-03-10 ウィスコンシン アラムナイ リサーチ ファンデーション ２−メチレン−２０−メチル−１９，２４，２５，２６，２７−ペンタノル−ビタミンｄ類縁体
EP2245029B1 (fr) 2008-02-20 2015-04-15 Novartis AG Inhibiteurs hétérocycliques de la stéaroyl-coa désaturase
JP2011518774A (ja) 2008-03-20 2011-06-30 フォレスト・ラボラトリーズ・ホールディングス・リミテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤としての新規ピペリジン誘導体
WO2009117659A1 (fr) 2008-03-20 2009-09-24 Forest Laboratories Holdings Limited Nouveaux dérivés de pipérazine en tant qu'inhibiteurs de stéaroyle-coa désaturase
EP2274308A1 (fr) 2008-04-04 2011-01-19 Gilead Sciences, Inc. Dérivés de pyrrolotriazinone pouvant être utilisés à titre d'inhibiteurs de stéaroyl-coa désaturase
US8088792B2 (en) 2008-04-04 2012-01-03 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
US20090253693A1 (en) 2008-04-07 2009-10-08 Dmitry Koltun 2H-BENZO[b][1,4]OXAZIN-3(4H)-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20110021532A1 (en) 2008-04-22 2011-01-27 Merck Frosst Canada Ltd. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
GB0810913D0 (en) 2008-06-13 2008-07-23 Smithkline Beecham Corp Comppounds
AU2009264242A1 (en) 2008-06-27 2009-12-30 Novartis Ag Organic compounds
FR2933979B1 (fr) 2008-07-15 2012-08-24 Pf Medicament Derives de triazines et uraciles, leur preparation et leur application en therapeutique humaine
WO2010007482A2 (fr) 2008-07-16 2010-01-21 Glenmark Pharmaceuticals S.A. Dérivés de thiazole en tant qu’inhibiteurs de stéaroyl-coa désaturase
JP2010043052A (ja) 2008-08-18 2010-02-25 Mitsubishi Chemicals Corp カロテノイド類の分離方法
WO2010025553A1 (fr) 2008-09-08 2010-03-11 Merck Frosst Canada Ltd. Composes heteroaromatiques utilises en tant qu'inhibiteurs de la stearoyle-coenzyme a delta-9 desaturase
WO2010028761A1 (fr) 2008-09-09 2010-03-18 Sanofi-Aventis Dérivés de 2-hétéro-aryl-pyrrolo[3, 4-c]pyrrol et leur utilisation en tant qu'inhibiteurs de scd
US20110184027A1 (en) 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
US20110166152A1 (en) 2008-10-02 2011-07-07 Jean-Philippe Leclerc Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2010045371A1 (fr) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Composés pyrido- et pyrimido (1, 2-a) pyrimidine utiles comme inhibiteurs de la stéaroyl-coa-désaturase
JP2012505881A (ja) 2008-10-15 2012-03-08 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための３−ヒドロキナゾリン−４−オン誘導体
WO2010045374A1 (fr) 2008-10-15 2010-04-22 Gilead Palo Alto, Inc. Dérivés de 3-hydroquinazoline-4-1 à utiliser comme inhibiteurs de la stéaroyl-coa-désaturase
AU2009304508A1 (en) 2008-10-17 2010-04-22 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
WO2010075356A1 (fr) 2008-12-23 2010-07-01 Forest Laboratories Holdings Limited Nouveaux dérivés de pipérazine constituant des inhibiteurs de stéaroyl-coa désaturase
AU2010215035B2 (en) 2009-02-17 2014-06-12 Merck Canada Inc. Novel spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
CA2750635A1 (fr) 2009-02-23 2010-08-26 Merck Canada Inc. Derives heterocycliques comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
US20120010186A1 (en) 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
JP2012522748A (ja) 2009-04-01 2012-09-27 ノバルティス アーゲー ステアロイル−ｃｏａデサチュラーゼ調節用スピロ誘導体
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
EP2459568A4 (fr) 2009-07-28 2013-02-27 Merck Frosst Canada Ltd Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
FR2948939B1 (fr) 2009-08-05 2013-03-22 Pf Medicament Derives de 2h pyridazin-3-ones, leur preparation et leur application en therapeutique humaine
AU2010289683C1 (en) 2009-09-01 2014-10-16 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
EP2475367A1 (fr) 2009-09-10 2012-07-18 Centre National De La Recherche Scientifique Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
WO2011039358A1 (fr) 2009-10-01 2011-04-07 Novartis Ag Dérivés de pyrazole qui modulent la stéaroyl-coa désaturase
WO2011047481A1 (fr) 2009-10-23 2011-04-28 Merck Frosst Canada Ltd. Nouveaux composés spiro utiles en tant qu'inhibiteurs de stéaroyl-coenzyme a delta-9 désaturase
FR2958935B1 (fr) 2010-04-19 2012-06-22 Pf Medicament Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine
US20130225618A1 (en) 2010-10-04 2013-08-29 Kowa Co., Ltd. Agent for inhibiting expression of lipid metabolism related mrna
US9102669B2 (en) 2011-12-06 2015-08-11 Janssen Pharmaceutica Nv Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors
WO2013085954A1 (fr) 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv Dérivés de pipéridinyl-carboxamide substitué utiles en tant qu'inhibiteurs de scd 1
WO2013134546A1 (fr) 2012-03-07 2013-09-12 Mayo Foundation For Medical Education And Research Procédés et matériaux pour traiter le cancer
NZ701133A (en) 2012-04-23 2016-08-26 Piramal Entpr Ltd Composition for treating metabolic disorders
RU2015122615A (ru) 2012-12-03 2017-01-10 Ф. Хоффманн-Ля Рош Аг Замещенные соединения амида изоксазола в качестве ингибиторов стеароил-коа-десатуразы 1 (скд1)
JP2016501210A (ja) 2012-12-03 2016-01-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｓｃｄ１の阻害剤としての置換イソオキサゾールアミン化合物
US9416102B2 (en) 2013-01-23 2016-08-16 Wisconsin Alumni Research Foundation (22E)-2-methylene-22-dehydro-1α,24,25-trihydroxy-19-nor-vitamin D3 analogs
KR101524650B1 (ko) 2013-07-30 2015-06-03 경상대학교산학협력단 테트라하이드로이소퀴놀린 알칼로이드계 화합물 ｙｓ－５１ｓ를 포함하는 대사성 질환의 예방 및 치료용 조성물
KR20150015305A (ko) 2013-07-31 2015-02-10 안동대학교 산학협력단 주박 추출물을 유효성분으로 함유하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
GB201403969D0 (en) 2014-03-06 2014-04-23 Isis Innovation Compounds for use in controlling body fat
CN106470990A (zh) 2014-03-12 2017-03-01 武田药品工业株式会社 哒嗪化合物
WO2016040794A1 (fr) 2014-09-12 2016-03-17 Whitehead Institute For Biomedical Research Cellules exprimant l'apolipoprotéine e et leurs utilisations
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof

Also Published As

Publication number Publication date
BR112019013954A2 (pt) 2020-02-11
EA201991650A1 (ru) 2020-01-20
AU2018205275B2 (en) 2024-05-02
EP3566055A4 (fr) 2020-12-02
US20180193325A1 (en) 2018-07-12
JP2020514293A (ja) 2020-05-21
CN110392833A (zh) 2019-10-29
KR20190108118A (ko) 2019-09-23
EP3566055A1 (fr) 2019-11-13
CA3049010A1 (fr) 2018-07-12
IL267818A (en) 2019-09-26
MX2019008124A (es) 2019-12-05
US20220040167A1 (en) 2022-02-10
AU2018205275A1 (en) 2019-07-25
US10973810B2 (en) 2021-04-13
JP2023036752A (ja) 2023-03-14
IL304017A (en) 2023-08-01
WO2018129403A1 (fr) 2018-07-12

Similar Documents

Publication Publication Date Title
HK1248116A1 (zh) 用於治療神經學疾病或紊亂的vmat2抑制劑
MA47212A (fr) Méthodes de traitement de troubles neurologiques
IL271085A (en) Bacteria to treat disorders
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA43532A (fr) Méthodes et compositions destinés au traitement de troubles liés à des crises épileptiques
SG11201608729RA (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
PT3119911T (pt) Compostos para uso no tratamento da doença de alzheimer em pacientes apoe4+/+
MA53329A (fr) Méthodes de traitement de l'épilepsie
ZA201903003B (en) Treatment of neurological diseases
IL267229A (en) Methods of treating ocular disorders
IL255506A (en) A method for treating a neurological disease
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
ES2893126T8 (es) Métodos de tratamiento de afecciones oculares
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
FR3039368B1 (fr) Procede de traitement cosmetique
MA47595A (fr) Méthodes de traitement d'affections neurodégénératives
IL264603A (en) Reelin preparations for the treatment of neurological diseases
IL263080B (en) Treatment of neurological disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA41094A (fr) Procédés de traitement de troubles rénaux
MA40065A (fr) N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson